Last reviewed · How we verify
Dermovat ointment
Dermovat ointment is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.
Dermovat ointment is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin. Used for Inflammatory and pruritic dermatological conditions (e.g., psoriasis, eczema, lichen planus).
At a glance
| Generic name | Dermovat ointment |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Topical corticosteroid (Class I/super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Dermovat contains clobetasol propionate, a potent Class I (super-potent) topical corticosteroid that binds to glucocorticoid receptors in skin cells, suppressing inflammatory cytokine production and immune cell infiltration. This reduces erythema, pruritus, and other inflammatory manifestations of dermatological conditions when applied topically.
Approved indications
- Inflammatory and pruritic dermatological conditions (e.g., psoriasis, eczema, lichen planus)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Systemic corticosteroid absorption (with prolonged use or occlusion)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dermovat ointment CI brief — competitive landscape report
- Dermovat ointment updates RSS · CI watch RSS
- LEO Pharma portfolio CI